Evidence map›Paper›PMID 25946021›Full record

ArticlePloS one2015

Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice.

Mara Kornete, Edward S Mason, Julien Girouard, Erin I Lafferty, Salman Qureshi, Ciriaco A Piccirillo

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Cytokines Associated with Activation of CD4International journal of molecular sciences · 2026
    Review
  2. Article
  3. Spectral Flow Cytometry: The Current State and Future of the Technology.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Changes of macrophage and CD4Scientific reports · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Regulatory T Cell Plasticity and Stability and Autoimmune Diseases.Clinical reviews in allergy & immunology · 2020
    Review
  19. ICOSFrontiers in immunology · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mara KorneteDepartment of Microbiology and Immunology, McGill University, Montréal, QC, Canada, H3A 2B4.
Edward S MasonDepartment of Microbiology and Immunology, McGill University, Montréal, QC, Canada, H3A 2B4.
Julien GirouardDepartment of Microbiology and Immunology, McGill University, Montréal, QC, Canada, H3A 2B4.
Erin I LaffertyDivision of Experimental Medicine, McGill University, Montreal, QC, Canada.
Salman QureshiDepartment of Medicine, McGill University, Montreal, QC, Canada.
Ciriaco A PiccirilloDepartment of Microbiology and Immunology, McGill University, Montréal, QC, Canada, H3A 2B4; Microbiome and Disease Tolerance Centre, McGill University, Montreal, QC, Canada, H3A 2B4; FOCIS Center of Excellence in Translational Immunology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, H3G 1A4.

Funding

Canadian Institutes of Health Research MOP-102494Canadian Institutes of Health Research MOP67211
6 · The paper itself

Abstract

Type 1 diabetes (T1D) occurs through a breakdown of self-tolerance resulting in the autoimmune destruction of the insulin producing β-islets of the pancreas. A numerical and functional waning of CD4+ Foxp3+ regulatory T (Treg) cells, prompted by a pancreatic IL-2 deficiency, accompanies Th1 autoimmunity and T1D progression in non-obese diabetic (NOD) mice. Recently, we identified a dominant subset of intra-islet Treg cells that expresses the ICOS costimulatory receptor and promotes self-tolerance delaying the onset of T1D. ICOS co-stimulation potently enhances IL-2 induced survival and proliferation, and suppressive activity of Treg cells in situ. Here, we propose an ICOS-dependent mechanism of Treg cell homing to the β-islets during pre-diabetes in the NOD model via upregulation of the CXCR3 chemokine receptor. The islet-specific ICOS+ Treg cell subset preferentially expresses CXCR3 in the pancreatic lymph nodes (pLN) in response to Teff cell-mediated pancreatic inflammation, an expression correlating with the onset and magnitude of IFN-γ production by Teff cells in pancreatic sites. We also reveal that intra-pancreatic APC populations and insulin-producing β, but not α nor δ, islet cells secrete the CXCR3 chemokines, CXCL9, 10 and 11, and selectively promote ICOS+ CXCR3+ Treg cell chemotaxis in vitro. Strikingly, islet-derived Treg cells also produce these chemokines suggesting an auto-regulation of homing by this subset. Unlike ICOS- cells, ICOS+ Treg cells adopt a Th1-like Treg phenotype while maintaining their suppressive capacity, characterized by expression of T-bet and CXCR3 and production of IFN-γ in the draining pLNs. Finally, in vivo neutralization of IFN-γ blocked Treg cell CXCR3 upregulation evincing its role in regulating expression of this chemokine receptor by Treg cells. Thus, CXCR3-mediated trafficking of Treg cells could represent a mechanism of homeostatic immunoregulation during diabetogeneesis.

Indexed as

Adoptive TransferAnimalsAutoimmunityCell MovementChemokine CXCL10Chemokine CXCL11Chemokine CXCL9Diabetes Mellitus, Type 1Inducible T-Cell Co-Stimulator ProteinInsulin-Secreting CellsInterferon-gammaInterleukin-2MiceMice, Inbred NODMice, TransgenicPrediabetic StateChemokine CXCL10Chemokine CXCL11Chemokine CXCL9Cxcl10 protein, mouseCxcl11 protein, mouseCxcl9 protein, mouseCxcr3 protein, mouseIcos protein, mouseInducible T-Cell Co-Stimulator ProteinInterferon-gammaInterleukin-2Receptors, CXCR3

Identifiers

PMID25946021
PMCPMC4422433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.